NCT05028894

23andMe IPF Research Study

23andMe Idiopathic Pulmonary Fibrosis Research Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 690 (actual)
• Sponsor: 23andMe, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Detailed description

This study will recruit 1,000 people who have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS). Eligible participants who consent to participate in 23andMe Research and the IPF Research Study will receive a 23andMe Health + Ancestry kit at no cost. Participants will provide a saliva sample and take a baseline survey online answering questions about their disease diagnosis, testing, treatment, and symptoms. Participants will also be asked to take the same survey 3, 6, and 9 months after completing the baseline survey. The data collected from this study will be incorporated into the 23andMe Database and used to better understand the underlying genetic and environmental factors that contribute to IPF.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
OTHER	No intervention	No intervention

Timeline

• Start date: 2020-06-05
• Primary completion: 2023-05-05
• Completion: 2023-05-05
• First posted: 2021-08-31
• Last updated: 2024-12-09

Locations

1 site across 1 country: United States